- Blood and genomic testing are becoming preferable means of early cancer screening and detection
- Leaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and Guardant
- AnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 different types of cancer
- One of the few companies offering multi-cancer tests for risk assessment and actually contributing to the fight against cancer by having its high risk individuals (tested first by its tests and later) confirmed in the healthcare providers for cancer patients and pre-cancer patients early
Almost 1.9 million new cancer cases will be diagnosed in the United States in 2021, according to American Cancer Society (“ACS”) estimates. This number excludes basal cell, squamous cell skin cancer, and carcinoma in situ except for urinary bladder cancer. The ACS also estimates that the number of Americans to die from cancer in 2021 will be 608,570, equivalent to 1,670 people per day (https://ibn.fm/qcO5q). To address these rising cancer rates, biotechnology companies in the U.S. and worldwide are focusing on the early detection and screening of cancer through the development of proprietary technologies.
AnPac Bio-Medical Science
The companies currently paving the way for early cancer screening and detection include AnPac Bio-Medical Science (NASDAQ: ANPC), Illumina, Inc.’s (NASDAQ: ILMN), Grail, Inc. (now part of Illumina), Exact Sciences Co., Ltd. (NASDAQ: EXAS), and…
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.